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Advances in hematopoietic cell transplantation (HCT) have led to an increasing number of transplant
survivors. To adequately support their healthcare needs, there is a need to know the prevalence of HCT
survivors. We used data on 170,628 recipients of autologous and allogeneic HCT reported to the Center for
International Blood and Marrow Transplant Research from 1968 to 2009 to estimate the current and future
number of HCT survivors in the United States. Stacked cohort simulation models were used to estimate the
number of HCT survivors in the United States in 2009 and to make projections for HCT survivors by the year
2030. There were 108,900 (range, 100,500 to 115,200) HCT survivors in the United States in 2009. This
included 67,000 autologous HCT and 41,900 allogeneic HCT survivors. The number of HCT survivors is esti-
mated to increase by 2.5 times by the year 2020 (242,000 survivors) and 5 times by the year 2030 (502,000
survivors). By 2030, the age at transplant will be < 18 years for 14% of all survivors (n ¼ 64,000), 18 to 59 years
for 61% survivors (n ¼ 276,000), and 60 years and older for 25% of survivors (n ¼ 113,000). In coming decades,
a large number of individuals will be HCT survivors. Transplant center providers, hematologists, oncologists,
primary care physicians, and other specialty providers will need to be familiar with the unique and complex
health issues faced by this population.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION related to pre-, peri-, and post-transplant treatment expo-
Of the 11.7 million people living with cancer in the United
States in 2007, 8% had hematologic malignancies [1]. For
selected patients with hematologic malignancies and other
disorders, hematopoietic cell transplantation (HCT) offers
the best chance of long-term survival. In the United States,
approximately 20,000 patients receive HCT each year [2].
Transplant activity has steadily increased over time with
introduction of safer transplant regimens, newer indications,
and alternative graft sources for hematopoietic stem cells.
Early and long-term survival after HCT has also improved
over time [3-7]. Patients who survive in remission for the
ﬁrst few years after transplantation have an 80% to 90%
probability of surviving over the following 10 to 15 years
[7-14]. However, these survivors continue to experience
increased morbidity and mortality from late complicationsedgments on page 1501.
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prevention [15-17].
A better understanding of the prevalence of HCT survi-
vors, which is presently not known, will help inform policy
and research in HCT survivorship. Issues that require atten-
tion include availability of healthcare resources needed for
survivor care, appropriate models of delivery of care, inte-
gration of primary care providers in survivor care, efﬁcacy
and acceptability of various screening and preventive prac-
tices, and healthcare costs associated with survivor care. We
used data from a national HCT clinical outcomes registry,
the Center for International Blood and Marrow Transplant
Research (CIBMTR), to calculate the current and future pre-
valence of HCT survivors in the United States.METHODS
Data Source
The CIBMTR is a research afﬁliation of the International Bone Marrow
Transplant Registry, Autologous Blood and Marrow Transplant Registry, and
the National Marrow Donor Program. Established in 2004, it comprises
a voluntary group of more than 450 centers worldwide that contribute
detailed data on consecutive HCTs to a Statistical Center at the Medical
College of Wisconsin in Milwaukee and the National Marrow DonorTransplantation.
Table 1
Prevalent Number of Hematopoietic Cell Transplant Recipients and Survivors in the United States by Year 2009
Characteristics Number of Recipients
Reported to CIBMTR n (%)
Estimated Total Number of
Recipients in the United States*,y n
Number of Survivorsy n (range)
Total number 170,628 266,200 108,900 (100,500-115,200)
Age at transplant, yr
<18 23,972 (14.1) 34,100 16,800 (15,800-17,700)
18-44 60,382 (35.5) 97,100 36,600 (32,300-39,100)
45-59 60,428 (35.6) 98,500 38,200 (34,900-40,300)
60 25,104 (17.8) 36,500 17,300 (16,600-18,100)
Missing 742 (.4) d d
Gender
Female 87,809 (51.5) 138,200 52,800 (45,800-56,000)
Male 82,300 (48.2) 128,000 56,100 (54,700-59,200)
Missing 519 (.3) d d
Diagnosis
Acute leukemia/myelodysplastic syndrome 44,850 (26.3) 60,500 22,400 (20,800-23,900)
Chronic myeloid leukemia 10,585 (6.2) 14,400 5400 (4300-6000)
Lymphoma 44,658 (26.2) 75,200 34,900 (31,700-36,600)
Multiple myeloma 27,635 (16.2) 42,700 23,100 (22,400-23,900)
Other 42,612 (25.0) 73,400 23,200 (21,400-24,800)
Missing 288 (.2) d d
Transplant/donor type
Autologous 101,946 (60.0) 166,700 67,000 (62,300-70,500)
Allogeneic related 38,899 (22.9) 61,000 25,100 (22,500-27,000)
Allogeneic unrelated 29,187 (17.2) 38,400 16,800 (15,700-17,700)
Missing 596 (.3) d d
* Correction factors were applied to account for partial reporting of clinical data by transplant centers to the CIBMTR (see Methods).
y Estimates rounded to the nearest hundreds.
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longitudinally with yearly follow-up. Computerized checks for errors,
physician reviews of submitted data, and on-site audits of participating
centers ensure data quality. Observational studies conducted by the CIBMTR
are in compliance with all applicable federal regulations pertaining to the
protection of human research participants as determined by continuous
review by the NationalMarrowDonor Program’s Institutional Review Board.
We included all ﬁrst HCT recipients in the United States from 1968 to
2009 that were registered with the CIBMTR in our analysis. All patients were
included, irrespective of diagnosis, transplant type (autologous or alloge-
neic), or donor source.
Because of varying policies, submission of data to the CIBMTR varied by
year since its inception but generally increased over time. For the time
period considered, the CIBMTR captured data on 50% to 80% of autologous,
50% to 100% of related donor, and 90% to 100% of unrelated donor HCT. Data
from other databases that capture center activity and hospital discharges
were used to apply correction factors for each year to extrapolate our esti-
mates of HCT recipients [2].
Statistical Analysis
We used a stacked cohort simulation model to estimate the number of
HCT recipients and survivors [18]. For this, we constructed the current
survivorship population by simulating cohorts of patients who received HCT
in each year from 1968 to 2009. Survival curves for each cohort were drawn
or projected out through 2009 and then “stacked” to estimate the preva-
lence of HCT survivors.
For prevalence estimate, we ﬁrst stratiﬁed our study population into
subgroups deﬁned by key prognostic factors (age at HCT, gender, diagnosis,
and transplant/donor type). Subgroups with similar survival curves that
included <200 patients were combined, in a hierarchy of age, gender,
diagnosis, and donor source, to obtain sufﬁcient statistical power in survival
analysis. Survival probabilities were estimated for a total of 61 such
subgroups. Next, for each subgroup, we used the survival curve to estimate
the annual probability of dying from all causes in a certain year after HCT. For
years where sufﬁcient follow-up was not available to draw the curve
through 2009, age-speciﬁc annual mortality rates and disease-speciﬁc
mortality rates were used to describe survival probability beyond the
survival curve. Finally, we calculated the number of survivors for each
subgroup accumulated up to the year 2009. After the matrix of survival
probabilities was constructed, the number of survivors for each year was
derived by multiplying the number of transplant recipients (corrected for
incomplete data reporting to CIBMTR) and the survival probability for that
year. The total number of survivors was the sum of all survivors for each year
up to the year 2009. The standard error of the survival probability was used
to estimate the lower and higher range for number of survivors. In the ﬁnalpresentation of our estimates, we combined subgroups into categories of
age at HCT, gender, diagnosis, and transplant/donor type. The Supplemental
Material highlights 1 subgroup to illustrate our methods.
For estimating future number of HCT survivors, we ﬁrst established
a regression equation to describe the pattern of transplant activity in the
United States from 2000 to 2009. We chose this year range because trans-
plant rates were most stable during this time period. In addition, this time
period reﬂected the use of HCT for contemporary indications and excludes
the inﬂuence of major practice changes on transplant utilization (eg,
decrease in allogeneic HCT rates for chronic myeloid leukemia with the
advent of imatinib and autologous HCT rates for breast cancer). We used this
equation to project the future number of HCT recipients until 2030. Next, we
used the method described above for prevalence analysis to estimate the
future number of survivors. Accumulated numbers of survivors by 2015,
2020, 2025, and 2030 were calculated by multiplying numbers of recipients
with survival probabilities for each year. Sensitivity analyses were per-
formed to assess the range of HCT survivors in response to the possible
future variation in rates of HCT after the year 2009.
RESULTS
Table 1 describes the prevalence of HCT survivors in the
United States in 2009. There were 108,900 (range, 100,500 to
115,200) HCT survivors in the United States in 2009. This
included 67,000 autologous HCT and 41,900 allogeneic HCT
survivors. Fifteen percent of survivors were <18 years of age
at the time of transplantation and 16%were 60 years of age or
older.
Figure 1 shows the projected number of survivors by year
2030. If the number of transplants performed continues to
increase at the current rate, we estimate a 2.5-fold increase
in the number of HCT survivors by 2020 and a 5-fold increase
by 2030. Figure 1 also demonstrates the estimated growth in
the number of survivors by transplant type and by age at
transplantation. Figure 2 shows results of sensitivity analyses
for how any changes in the future utilization of HCT might
affect the estimated survivor projections.
DISCUSSION
The cancer survivor population in the United States is
expected to grow to 18 million by 2022 [19], and, based on
Figure 1. Projected number of hematopoietic cell transplant survivors in the
US by year 2030 for (A) all survivors, (B) survivors by transplant type, and (C)
survivors by age at transplant.
Figure 2. Sensitivity analyses showing how any future changes in the rate of
transplant activity would affect the projected estimates for survivors in the
United States by year 2030.
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of HCT survivors. HCT survivors can face a lifetime of
potential health problems. Extensive research has been
performed and is presently ongoing to better understand the
incidence, risk factors, morbidity, and mortality associated
with late complications such as secondary cancers, infec-
tions, bone loss, and cardiac, endocrine, renal, and pulmo-
nary dysfunction [15,20-23]. Risk for many complications
increases with time because transplantation and lifelong
surveillance and follow-up of HCT survivors is recommended
for their prevention and timely management [15,16]. Ade-
quate personnel, infrastructure, and resources are needed to
meet the long-term healthcare needs of transplant survivors.Our estimates will assist transplant centers, other providers,
and policymakers plan for the present number and future
growth in survivor population.
With the increasing number of patients who need
transplantation, many transplant centers have to focus their
limited resources toward the early post-transplant care of
HCT recipients. Centers frequently lack the capacity and
physician and other personnel support for the long-term
follow-up of HCT survivors [24-26]. Hence, close coordina-
tion between transplant centers, referring hematologist-
oncologists, primary care and specialty providers, and
patients is needed for long-term survivor care. It is also
important that nontransplant providers are familiar with the
unique and complex health issues faced by this population
and with guidelines for their preventive care [16,17]. Inno-
vative patient-centeredmodels for delivery of long-term care
for HCT survivors that integrate transplant and nontrans-
plant providers need to be studied.
HCT is a rapidly evolving ﬁeld, and research advances
can substantially decrease (eg, introduction of imatinib
for treatment of chronic myeloid leukemia) or increase
(eg, introduction of alternate graft sources and non-
myeloablative/reduced-intensity conditioning regimens)
transplant utilization. In fact, the rates of HCT for older
patients using nonmyeloablative/reduced-intensity regi-
mens have increased dramatically even since 2009, the last
year of HCT included in our analysis. Overall, HCT activity
in the United States has steadily increased over the last
decade. As transplant centers and policymakers plan for
survivor care, our sensitivity analyses will provide them
with estimates on how any changes in HCT utilization will
impact future survivor prevalence. Furthermore, research
advances continuously impact HCT practice and the proﬁle
of HCT recipients, and our analysis will need to be updated
periodically to keep abreast with these changes.
Chronic graft-versus-host disease is an important deter-
minant of late mortality in allogeneic HCT recipients and also
contributes signiﬁcantly to the development of late compli-
cations [7,8,15]. We were not able to estimate survivor
prevalence based on chronic graft-versus-host disease status
and how any future advancements in prevention and treat-
ment of chronic graft-versus-host disease might impact
predictions of number of transplant survivors. Future re-
search should address this issue.
In conclusion, our analysis represents the ﬁrst estimate of
prevalence of HCT survivors in the United States. It is our
N.S. Majhail et al. / Biol Blood Marrow Transplant 19 (2013) 1498e1501 1501hope that this analysis will greatly facilitate policy and
research in HCT survivorship.
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